Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -416.41% is 150% below its 5-year average of -166.69%, near the high end of its 5-year range (-2871.75%–-6.84%).
26.21% below its 12-month average of -329.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -219.96%.
EBITDA MARGIN
-416.41%
EBITDA MARGIN AVG TTM
-329.93%
EBITDA MARGIN AVG 3Y
-209.89%
EBITDA MARGIN AVG 5Y
-166.69%
EBITDA MARGIN AVG 10Y
-119.91%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-26.21%
CURRENT VS 3Y AVG
-98.39%
CURRENT VS 5Y AVG
-149.81%
CURRENT VS 10Y AVG
-247.28%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Coherus Oncology, Inc.
Market Cap
$164.54M
EBITDA Margin
-416.41%
TTM Avg
-329.93%
3Y Avg
-209.89%
5Y Avg
-166.69%
Market Cap
$169.48M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$170.03M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$170.72M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$171.77M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$172.60M
EBITDA Margin
-6455.53%
TTM Avg
-6455.53%
3Y Avg
-6455.53%
5Y Avg
-6455.53%
Market Cap
$155.86M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.71M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $164.54M | -416.41% | -329.93% | -209.89% | -166.69% |
| Nkarta, Inc. (NKTX)vs › | $169.48M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| Precision BioSciences, Inc. (DTIL)vs › | $170.03M | -144.16% | -87.79% | -115.19% | -149.65% |
| Cue Biopharma, Inc. (CUE)vs › | $170.72M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Inogen, Inc. (INGN)vs › | $157.47M | -2.74% | -4.58% | -13.60% | -7.28% |
| MediWound Ltd. (MDWD)vs › | $171.77M | -138.09% | -113.30% | -81.67% | -67.39% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.60M | -6455.53% | -6455.53% | -6455.53% | -6455.53% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.71M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Minerva Neurosciences, Inc. (NERV)vs › | $153.61M | 4.91% | 4.91% | 4.91% | 4.91% |
Gross Margin
63.5%
EBITDA Margin
-416.4%
Operating Margin
-425.7%
Net Margin
-257.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -219.96% |
| 2026-03-31 | -286.52% |
| 2025-12-31 | -352.87% |
| 2025-09-30 | -356.64% |
| 2025-06-30 | -433.68% |
| 2025-03-31 | -584.14% |
| 2024-12-31 | -76.12% |
| 2024-09-30 | -6.84% |
| 2024-06-30 | -29.74% |
| 2024-03-31 | -2871.75% |
| 2023-12-31 | -74.12% |
| 2023-09-30 | -40.73% |
| 2023-06-30 | -57.33% |
| 2023-03-31 | -205.93% |
| 2022-12-31 | -111.23% |
| 2022-09-30 | -174.92% |
| 2022-06-30 | -71.70% |
| 2022-03-31 | -133.34% |
| 2021-12-31 | -52.76% |
| 2021-09-30 | -38.66% |
| 2021-06-30 | -26.57% |
| 2021-03-31 | -200.53% |
| 2020-12-31 | 15.64% |
| 2020-09-30 | 30.30% |
| 2020-06-30 | 48.69% |
| 2020-03-31 | 35.70% |
| 2019-12-31 | 37.21% |
| 2019-09-30 | 47.17% |
| 2019-06-30 | 33.76% |
| 2019-03-31 | -42.88% |
| 2017-06-30 | -4000.07% |
| 2017-03-31 | -44442.24% |
| 2016-12-31 | -8609.36% |
| 2016-09-30 | 52.43% |
| 2016-06-30 | -440.77% |
| 2016-03-31 | -514.89% |
| 2015-12-31 | -506.04% |
| 2015-09-30 | -984.81% |
| 2015-06-30 | -851.95% |
| 2015-03-31 | -628.50% |
| 2014-12-31 | -405.44% |
| 2014-09-30 | -38.82% |
| 2014-06-30 | -358.65% |
| 2014-03-31 | -379.45% |
| 2013-12-31 | -842.45% |
| 2013-09-30 | -1320.55% |
| 2013-06-30 | -1811.64% |
| 2013-03-31 | -1846.44% |
